Title:
NOVEL ANGIOGENIC STEM CELL
Document Type and Number:
WIPO Patent Application WO/2024/080661
Kind Code:
A1
Abstract:
The present invention relates to vMSC, which is a stem cell that is newly identified and has angiogenic properties. vMSCs cultured under specific culture conditions and identified, according to the present invention, are novel MSCs that express a CD141 cell surface antigen, unlike conventional MSCs, and the vMSC has excellent cell expansion ability, has a direct angiogenic effect, and has an autocrine effect unlike conventional stem cells, as well as a paracrine effect by other MSCs. Thus, the vMSCs have a higher survival and retention rate in tissues than conventional stem cell therapeutic agents, and can be used as a stem cell therapeutic agent for blood vessel regeneration that directly forms blood vessels.
Inventors:
YIM SUNG VIN (KR)
HONG HYUN SOOK (KR)
HWANG DAE YEON (KR)
SON YOUNG SOOK (KR)
PARK KI SOOK (KR)
PARK GA BEE (KR)
HONG SEON MIN (KR)
KIM DAE WOOK (KR)
HONG HYUN SOOK (KR)
HWANG DAE YEON (KR)
SON YOUNG SOOK (KR)
PARK KI SOOK (KR)
PARK GA BEE (KR)
HONG SEON MIN (KR)
KIM DAE WOOK (KR)
Application Number:
PCT/KR2023/015279
Publication Date:
April 18, 2024
Filing Date:
October 05, 2023
Export Citation:
Assignee:
ELPHIS CELL THERAPEUTICS (KR)
International Classes:
C12N5/0775; A61K35/28; A61K35/545; A61K38/18; A61L27/38; A61L27/50; A61P9/00; A61P25/00
Domestic Patent References:
| WO2015016785A1 | 2015-02-05 |
Foreign References:
| KR20170020273A | 2017-02-22 | |||
| KR20180004319A | 2018-01-10 | |||
| US20170296587A1 | 2017-10-19 | |||
| KR20150009656A | 2015-01-27 | |||
| KR20210116350A | 2021-09-27 |
Attorney, Agent or Firm:
WIE, Byoung Gap (KR)
Download PDF: